|
1
|
Markopoulos AK: Current aspects on oral
squamous cell carcinoma. Open Dent J. 6:126–130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demokan S and Dalay N: Role of DNA
methylation in head and neck cancer. Clin Epigenetics. 2:123–150.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
González-Ramírez I, García-Cuellar C,
Sánchez-Pérez Y and Granados-García M: DNA methylation in oral
squamous cell carcinoma: molecular mechanisms and clinical
implications. Oral Dis. 17:771–778. 2011.PubMed/NCBI
|
|
6
|
Lister R, Pelizzola M, Dowen RH, Hawkins
RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, Edsall
L, Antosiewicz-Bourget J, Stewart R, Ruotti V, Millar AH, Thomson
JA, Ren B and Ecker JR: Human DNA methylomes at base resolution
show widespread epigenomic differences. Nature. 462:315–322. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weber M, Davies JJ, Wittig D, Oakeley EJ,
Haase M, Lam WL and Schubeler D: Chromosome-wide and
promoter-specific analyses identify sites of differential DNA
methylation in normal and transformed human cells. Nat Genet.
37:853–862. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bird A: DNA methylation patterns and
epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar
|
|
9
|
Carvalho RH, Haberle V, Hou J, van Gent T,
Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts
A, Foekens J, van Vroonhoven M, Aerts J, Grosveld F, Lenhard B and
Philipsen S: Genome-wide DNA methylation profiling of non-small
cell lung carcinomas. Epigenetics Chromatin. 5:92012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rosas SL, Koch W, da Costa Carvalho MG, Wu
L, Califano J, Westra W, Jen J and Sidransky D: Promoter
hypermethylation patterns of p16,
O6-methylguanine-DNAmethyltransferase, and death-associated protein
kinase in tumors and saliva of head and neck cancer patients.
Cancer Res. 61:939–942. 2001.
|
|
11
|
Jacinto FV, Ballestar E and Esteller M:
Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA
methylome. Biotechniques. 44:35–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sardi I, Dal Canto M, Bartoletti R and
Montali E: Abnormal c-myc oncogene DNA methylation in human bladder
cancer: possible role in tumor progression. Eur Urol. 31:224–230.
1997.PubMed/NCBI
|
|
14
|
Kresty LA, Mallery SR, Knobloch TJ, Song
H, Lloyd M, Casto BC and Weghorst CM: Alterations of p16(INK4a) and
p14(ARF) in patients with severe oral epithelial dysplasia. Cancer
Res. 62:5295–5300. 2002.PubMed/NCBI
|
|
15
|
Palmisano WA, Divine KK, Saccomanno G,
Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung
cancer by detecting aberrant promoter methylation in sputum. Cancer
Res. 60:5954–5958. 2000.PubMed/NCBI
|
|
16
|
Cheng YY, Jin H, Liu X, Siu JM, Wong YP,
Ng EK, Yu J, Leung WK, Sung JJ and Chan FK: Fibulin 1 is
downregulated through promoter hypermethylation in gastric cancer.
Br J Cancer. 99:2083–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pupa SM, Argraves WS, Forti S, Casalini P,
Berno V, Agresti R, Aiello P, Invernizzi A, Baldassari P, Twal WO,
Mortarini R, Anichini A and Menard S: Immunological and
pathobiological roles of fibulin-1 in breast cancer. Oncogene.
23:2153–2160. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wlazlinski A, Engers R, Hoffmann MJ, Hader
C, Jung V, Muller M and Schulz WA: Downregulation of several
fibulin genes in prostate cancer. Prostate. 67:1770–1780. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Twal WO, Czirok A, Hegedus B, Knaak C,
Chintalapudi MR, Okagawa H, Sugi Y and Argraves WS: Fibulin-1
suppression of fibronectin-regulated cell adhesion and motility. J
Cell Sci. 114:4587–4598. 2001.PubMed/NCBI
|
|
21
|
Veeck J, Chorovicer M, Naami A, Breuer E,
Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A,
Knuechel R and Dahl E: The extracellular matrix protein ITIH5 is a
novel prognostic marker in invasive node-negative breast cancer and
its aberrant expression is caused by promoter hypermethylation.
Oncogene. 27:865–876. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Himmelfarb M, Klopocki E, Grube S, Staub
E, Klaman I, Hinzmann B, Kristiansen G, Rosenthal A, Dürst M and
Dahl E: ITIH5, a novel member of the inter-alpha-trypsin inhibitor
heavy chain family is downregulated in breast cancer. Cancer Lett.
204:69–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamm A, Veeck J, Bektas N, Wild PJ,
Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del
Maestro R, Knuechel R and Dahl E: Frequent expression loss of
Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple
human solid tumors: a systematic expression analysis. BMC Cancer.
8:252008. View Article : Google Scholar
|
|
24
|
Tsunematsu T, Kudo Y, Iizuka S, Ogawa I,
Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic
role in head and neck cancer. PLoS One. 4:e58922009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li QL, Ito K, Sakakura C, Fukamachi H,
Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ,
Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe
T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima
T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3
expression and gastric cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK,
Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX3, a novel tumor
suppressor, is frequently inactivated in gastric cancer by protein
mislocalization. Cancer Res. 65:7743–7750. 2005.PubMed/NCBI
|
|
27
|
Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li
QL, Yang JO, Ito Y and Bae SC: RUNX3 inactivation by point
mutations and aberrant DNA methylation in bladder tumors. Cancer
Res. 65:9347–9354. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen W, Gao N, Shen Y and Cen JN:
Hypermethylation downregulates Runx3 gene expression and its
restoration suppresses gastric epithelial cell growth by inducing
p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol.
25:823–831. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mori T, Nomoto S, Koshikawa K, Fujii T,
Sakai M, Nishikawa Y, Inoue S, Takeda S, Kaneko T and Nakao A:
Decreased expression and frequent allelic inactivation of the RUNX3
gene at 1p36 in human hepatocellular carcinoma. Liver Int.
5:380–388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shiraha H, Nishina S and Yamamoto K: Loss
of runt-related transcription factor 3 causes development and
progression of hepatocellular carcinoma. J Cell Biochem.
112:745–749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nishina S, Shiraha H, Nakanishi Y, Tanaka
S, Matsubara M, Takaoka N, Uemura M, Horiguchi S, Kataoka J,
Iwamuro M, Yagi T and Yamamoto K: Restored expression of the tumor
suppressor gene RUNX3 reduces cancer stem cells in hepatocellular
carcinoma by suppressing Jagged1-Notch signaling. Oncol Rep.
26:523–531. 2011.PubMed/NCBI
|
|
32
|
Ku JL, Kang SB, Shin YK, Kang HC, Hong SH,
Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation
downregulates RUNX3 gene expression in colorectal cancer cell
lines. Oncogene. 23:6736–6742. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee CW, Ito K and Ito Y: Role of RUNX3 in
bone morphogenetic protein signaling in colorectal cancer. Cancer
Res. 70:4243–4252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yanada M, Yaoi T, Shimada J, Sakakura C,
Nishimura M, Ito K, Terauchi K, Nishiyama K, Itoh K and Fushiki S:
Frequent hemizygous deletion at 1p36 and hypermethylation
downregulate RUNX3 expression in human lung cancer cell lines.
Oncol Rep. 14:817–822. 2005.PubMed/NCBI
|
|
35
|
Ginos MA, Page GP, Michalowicz BS, Patel
KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL and Gaffney PM:
Identification of a gene expression signature associated with
recurrent disease in squamous cell carcinoma of the head and neck.
Cancer Res. 64:55–63. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salto-Tellez M, Peh BK, Ito K, Tan SH,
Chong PY, Han HC, Tada K, Ong WY, Soong R, Voon DC and Ito Y: RUNX3
protein is overexpressed in human basal cell carcinomas. Oncogene.
25:7646–7649. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee CW, Chuang LS, Kimura S, Lai SK, Ong
CW, Yan B, Salto-Tellez M, Choolani M and Ito Y: RUNX3 functions as
an oncogene in ovarian cancer. Gynecol Oncol. 122:410–417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kudo Y, Tsunematsu T and Takata T:
Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem.
112:387–393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ito K: RUNX3 in oncogenic and
anti-oncogenic signaling in gastrointestinal cancers. J Cell
Biochem. 112:1243–1249. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito
K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito
Y and Sukumar S: RUNX3 is frequently inactivated by dual mechanisms
of protein mislocalization and promoter hypermethylation in breast
cancer. Cancer Res. 66:6512–6520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo B, Godzik A and Reed JC: Bcl-G, a
novel pro-apoptotic member of the Bcl-2 family. J Biol Chem.
276:2780–2785. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pickard MR, Edwards SE, Cooper CS and
Williams GT: Apoptosis regulators Fau and Bcl-G are down-regulated
in prostate cancer. Prostate. 70:1513–1523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pickard MR, Green AR, Ellis IO, Caldas C,
Hedge VL, Mourtada-Maarabouni M and Williams GT: Dysregulated
expression of Fau and MELK is associated with poor prognosis in
breast cancer. Breast Cancer Res. 11:R602009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ikeda J, Oda T, Inoue M, Uekita T, Sakai
R, Okumura M, Aozasa K and Morii E: Expression of CUB domain
containing protein (CDCP1) is correlated with prognosis and
survival of patients with adenocarcinoma of lung. Cancer Sci.
100:429–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Perry SE, Robinson P, Melcher A, Quirke P,
Bühring HJ, Cook GP and Blair GE: Expression of the CUB domain
containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS
Lett. 581:1137–1142. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ikeda JI, Morii E, Kimura H, Tomita Y,
Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T
and Aozasa K: Epigenetic regulation of the expression of the novel
stem cell marker CDCP1 in cancer cells. J Pathol. 210:75–84. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seidel J, Kunc K, Possinger K, Jehn C and
Lüftner D: Effect of the tyrosine kinase inhibitor lapatinib on
CUB-domain containing protein (CDCP1)-mediated breast cancer cell
survival and migration. Biochem Biophys Res Commun. 414:226–232.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yuan J, Luo RZ, Fujii S, Wang L, Hu W,
Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC
Jr and Yu Y: Aberrant methylation and silencing of ARHI, an
imprinted tumor suppressor gene in which the function is lost in
breast cancers. Cancer Res. 63:4174–4180. 2003.PubMed/NCBI
|
|
49
|
Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y,
Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB and Bast RC Jr:
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in
ovarian and breast carcinomas. Proc Natl Acad Sci USA. 96:214–219.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Luo RZ, Fang X, Marquez R, Liu SY, Mills
GB, Liao WS, Yu Y and Bast RC: ARHI is a Ras-related small
G-protein with a novel N-terminal extension that inhibits growth of
ovarian and breast cancers. Oncogene. 22:2897–2909. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Huang J, Lin Y, Li L, Qing D, Teng XM,
Zhang YL, Hu X, Hu Y, Yang P and Han ZG: ARHI, as a novel
suppressor of cell growth and downregulated in human hepatocellular
carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog.
48:130–140. 2009. View Article : Google Scholar : PubMed/NCBI
|
